Patients with CALR mutated ET are also younger, have a lower risk for thrombosis, and show no progression to PV (vs. 29% at 15 years), assuming that JAK2-positive ET and PV are different stages/phenotypes of a single disease, and CALR-positive ET is a different nosological entity [133]. The gene discussed is CALR; the disease is acquired polycythemia vera.